Cancer has always been a terrible disease. In the past, the choice of cancer treatment mainly included surgery, chemotherapy and radiotherapy, and the emergence of "targeted drugs" became another choice for many cancer treatments.
B-Raf kinase inhibitor kinase can effectively inhibit tumor growth.
A new breakthrough has been made in the research and development of individualized anticancer drugs in China. The targeted drug of B-Raf kinase inhibitor kinase inhibitor developed by Biotechnology Center has been proved by research that it can selectively poison cancer cells with BRAF gene variation, effectively inhibit tumor growth at low oral dose, and the drug is safe. The Biotechnology Center announced on June 5438+08 that the R&D technology will be transferred to Lianya Medicine (6562), and it is expected that the market application potential of cancer targeted therapy will be huge in the future.
B-Raf kinase inhibitor is a popular anti-cancer targeted drug at present. Gan Liangsheng, CEO of Biotechnology Center, said that drug development is an international competition. In the face of competitors from all over the world, only the drugs developed are novel, effective, safe and internationally competitive, and the new drugs developed are truly valuable. The new anticancer drug RAF inhibitor developed by Biotechnology Center is novel, effective and safe, with deep international competitiveness and high industrial value. Li, director of the Institute of Chemistry and Medicine of the Biotechnology Center, said that with the support of the special plan of the Ministry of Economic Affairs, B-RAF kinase inhibitor, a patented and internationally competitive targeted drug, is superior to Vemurafenib and Dabrafenib, which are currently listed in the market, in terms of specificity, effectiveness and anti-cancer activity in vivo, and is confirmed to be safer than other anti-cancer drugs by preclinical toxicology tests. Relevant information has been collected so far. After the clinical trial plan is completed recently, an application for human clinical trial will be submitted to the US Food and Drug Administration (USFDA) and the Health and Welfare Department of the Food and Drug Administration (TFDA). The estimated time may be as long as 65,438+00 years.
Targeted drugs: act on tumor growth-related sites to inhibit tumors, including tumor growth-related receptors, gene or information transmission pathways, tumor angiogenesis factors, etc.